Douglas Ball, Chairman and Chief Executive Officer, founded ZBx in 2002 and is responsible for executive and strategic direction. He was a co-founder of Spectral Diagnostics, taking it from a concept stage in 1991 to become the first Canadian diagnostic company to be listed on the NASDAQ exchange in 1994. Spectral created the first cardiac specific Troponin I rapid test for myocardial infarction which received FDA, Health Canada and European CE approvals. He served as Spectral’s Chairman and CEO until 2000, managing acquisitions of technologies, strategic partnerships and joint venture manufacturing. Before Spectral he was a strategy and turnaround consultant, a Vice President of Leveraged Finance at Citibank Canada and a Representative with Bank of Nova Scotia at its Wall Street Office. He has a BA in Economics and a BA in Commerce from Carleton University and a MA in Policy Analysis from the New School for Social Research in New York City.
Chris Plaxton, President and Chief Operating Officer, focuses on strategic partnering and negotiations and finance. From 1994 to 2001 he was Executive Vice President for Commercialization and Operations at Spectral Diagnostics, where he established distribution networks, Canadian and US sales forces, technology exploitation and licensing programs, and directed manufacturing and the regulatory submission process. Prior to 1994, he was a senior partner with the public accounting and consulting firm, Coopers & Lybrand (a PWC predecessor company), specializing in the provision of consulting, audit and SEC and Ontario Securities Commission services to bio-pharmaceuticals and biotechnology companies. Mr. Plaxton is a Chartered Accountant and has a Bachelor of Applied Sciences degree in chemical engineering from the University of Toronto.
Dr. Qinwei Shi, Executive Vice President, Research and Development is responsible for the invention and continual improvement of the ZBx’s ZAP™ rapid diagnostic test system as well as managing all aspects of the scientific affairs, research and development and manufacturing at the Corporation. Between 1994 and 2002, Dr. Shi was responsible for molecular biology, protein engineering, development of immunoassays, designing and producing diagnostic reagents, platform development and supervision of research activities at Spectral Diagnostics Inc. Dr. Shi received his MD from the Shanxi Medical Untversity, a Ph.D. in Clinical Biochemistry from the University of Toronto and completed Post Doctoral work in the Department of Genetics at The Hospital For Sick Children, Toronto with a focus on the genetics of Duchenne muscular dystrophy. He is an author or co-author of 17 peer reviewed papers, 25 abstracts and two book chapters and the sole inventor or co-inventor on 16 patent families.